Menu
Recruiting NCT06118892

MISHA Post-Market Clinical Study

No phase Interventional Osteo Arthritis Knee

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: MISHA Knee System.
Who it may be relevant to
Registry conditions: Osteo Arthritis Knee. Basic parameters: 25 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Post-Market Evaluation of the MISHA® Knee System for Symptom Relief in Subjects With Medial Knee Osteoarthritis

Overview

Prospective evaluation of the safety and effectiveness of the MISHA Knee System. The study will collect data on the procedural and long-term adverse events, WOMAC pain and function scores, KSS satisfaction, subsequent surgical interventions, BMI levels, range of motion, UCLA activity level of the subjects, and perform radiographic/x-ray evaluations at clinical visits through 5 years post-procedure. The primary analysis of this study is freedom from device- and procedure-related SSIs at five (5) years post-implantation. This study will also assess device performance in subjects with intact and retained devices and subjects with devices removed prior to study termination and freedom from conversion to arthroplasty through 5 years. Study subjects will be followed over a five-year post-implant period.

Interventions

  • Device MISHA Knee System
    The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.

Primary outcome measures

  • Freedom from device- and procedure-related Subsequent Surgical Interventions [Time frame: 5 years post-implantation]
Secondary outcome measures (2)
  • WOMAC Pain [Time frame: 5 years]
  • WOMAC Function [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • Subjects aged 25 to 65 years at time of index procedure
  • Body Mass Index (BMI) of < 35
  • Activity exacerbated knee pain isolated to the medial compartment and not global in nature
  • WOMAC pain ≥ 40
  • Failed non-operative OA treatment

Exclusion criteria

  • Large medial osteophyte(s) or considerable extruded meniscus that may interfere with the placement or function of the device
  • Poor bone quality (e.g., bony erosion, osteopenia, osteoporosis)
  • Ligamentous instability
  • Active or recent knee infection
  • Inflammatory joint disease, including sequalae of viral infections
  • Suspected or documented allergy or hypersensitivity to cobalt, chromium, nickel or other metals
  • History of keloid, hypertrophic or contracture scaring
  • Propensity for restrictive scar formation or adhesions with prior procedures

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 4 centers
  • Weiss Orthopedics — Sonoma
  • Orthopaedics Specialists of NC — Raleigh
  • Oregon Health and Science University — Portland
  • University of Virginia — Charlottesville

Identifiers

NCT: NCT06118892 · CP0009

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗